Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL21747582 | 1.00 | MEN1 (0.47) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL29811219 | 0.95 | MEN1 (0.47) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL2228243 | 0.95 | MEN1 (0.47) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL2228246 | 0.95 | MEN1 (0.47) | MEN1BLMKMT2ANOS2NOS3 | |
| Pipecolic Acid SCHEMBL7136695 | 0.93 | BLM (0.41) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL28049461 | 0.93 | MEN1 (0.48) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL718906 | 0.93 | BLM (0.52) | MEN1BLMKMT2ANOS2NOS3 | |
| D-Proline SCHEMBL21462052 | 0.93 | BLM (0.52) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL2939 | 0.93 | — | — | |
| Proline SCHEMBL13248912 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749675-A1 | CO-CRYSTAL FORMS OF A NOVOBIOCIN ANALOG AND PROLINE | Reata Pharmaceuticals, Inc. (US) | 2020-12-16 | — | — | EP | claimed |
| CN-112020506-A | Co-crystal form of neomycin analog and proline | 里亚塔医药公司 | 2020-12-01 | — | — | CN | claimed |
| US-20200347088-A1 | CO-CRYSTAL FORMS OF A NOVOBIOCIN ANALOG AND PROLINE | REATA PHARMACEUTICALS, INC. | 2020-11-05 | — | — | US | claimed |
| US-10717755-B2 | Co-crystal forms of a novobiocin analog and proline | REATA PHARMACEUTICALS, INC. (US) | 2020-07-21 | — | — | US | claimed |
| WO-2019156907-A1 | CO-CRYSTAL FORMS OF A NOVOBIOCIN ANALOG AND PROLINE | REATA PHARMACEUTICALS, INC. (US) | 2019-08-15 | — | — | WO | claimed |
| US-20190241599-A1 | CO-CRYSTAL FORMS OF A NOVOBIOCIN ANALOG AND PROLINE | REATA PHARMACEUTICALS, INC. | 2019-08-08 | — | — | US | claimed |
| CN-112638934-B | Solution phase Path for WNT hexapeptide | 温特研究公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11970551-B2 | Solution phase routes for WNT hexapeptides | WNTRESEARCH AB (SE) | 2024-04-30 | — | — | US | disclosed |
| US-11912791-B2 | Solution phase routes for Wnt hexapeptides | WNTRESEARCH AB (SE) | 2024-02-27 | — | — | US | disclosed |
| US-20230295232-A1 | SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | WNTRESEARCH AB (SE) | 2023-09-21 | — | — | US | disclosed |
| EP-3841107-B1 | SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | WNTRESEARCH AB (SE) | 2023-06-28 | — | — | EP | disclosed |
| EP-3841107-A1 | SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | Wntresearch AB (SE) | 2021-06-30 | — | — | EP | disclosed |
| US-20210171575-A1 | SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | WNTRESEARCH AB (SE) | 2021-06-10 | — | — | US | disclosed |
| CN-112638934-A | Solution phase route for WNT hexapeptides | 温特研究公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020038878-A1 | SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | WNTRESEARCH AB (SE) | 2020-02-27 | — | — | WO | disclosed |
| EP-3613757-A1 | SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | Wntresearch AB (SE) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717755-B2 | Co-crystal forms of a novobiocin analog and proline | PDXK, PLPBP, IAPP | MEN1 4370/4885BLM 1017/4885KMT2A 3851/4885 |
| US-20190241599-A1 | CO-CRYSTAL FORMS OF A NOVOBIOCIN ANALOG AND PROLINE | PDXK, PLPBP, IAPP | MEN1 4370/4885BLM 1017/4885KMT2A 3851/4885 |
| US-20200347088-A1 | CO-CRYSTAL FORMS OF A NOVOBIOCIN ANALOG AND PROLINE | PDXK, PLPBP, IAPP | MEN1 4370/4885BLM 1017/4885KMT2A 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.